# Next-generation Sequencing Services Market

> Next-Generation Sequencing Services Market Research Report By Service Type (Human Genome Sequencing Services, Single-Cell Sequencing Services, Microbial Genome-Based Sequencing Services, Gene Regulation Services, Other Service Type), By Technology (Sequencing-by-Synthesis (SBS), Ion Semiconductor Sequencing, Nanopore Sequencing, Single-Molecule Real-Time (SMRT) Sequencing), By Application (Clinical Diagnostics, Drug Discovery & Development, Agriculture & Environmental, Biotechnology & Genetic Research and Other Applications), By End User (Hospitals & Clinics, Pharmaceutical & Biotech Companies, Clinical Diagnostic Laboratories, Academic and Research Institutions, Other End Users) - Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 13.4%
- **2025:** USD 5.71 Billion
- **2035:** USD 20.25 Billion
- **Key Players:** Illumina, BGI Genomics, Eurofins Scientific, Thermo Fisher Scientific, Azenta Life Sciences, Novogene, Labcorp, Quest Diagnostics

**Report ID:** MRFR/MRO/65604-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** October 31, 2026

**URL:** https://www.marketresearchfuture.com/reports/next-generation-sequencing-services-market-67403

---

## Market Summary

## Next-generation Sequencing Services Market Summary

The [Next Generation Sequencing](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354) Services Market was valued at USD 5.71 Billion in 2025 and is projected to reach USD 6.53 Billion in 2026, rising to USD 20.25 Billion by 2035 at a CAGR of 13.4% over 2026–2035. Two catalysts anchor this outlook. Medicare's National Coverage Determination 90.2 guarantees payment for FDA-approved NGS companion diagnostics in advanced cancer [3]. National programs such as the NIH All of Us Research Program, which released roughly 245,000 whole genomes to researchers in 2024, also keep service laboratories running at high utilization [16].

Sanger sequencing, microarrays, and narrow single-gene tests are steadily giving way to whole-exome, whole-genome, and long-read workflows. [Illumina](https://www.illumina.com/services/sequencing-services.html)'s NovaSeq X Series brought the reagent cost of a human genome close to USD 200 [1], while NHGRI data show sequencing costs falling faster than Moore's Law for more than a decade [2]. Lower unit costs make precision medicine sequencing viable for community hospitals and mid-sized biotech firms that previously could not justify in-house capacity, so they outsource instead.

North America leads with a 44.6% share in 2025, supported by reimbursement depth and a dense base of accredited laboratories. Asia-Pacific is the fastest-growing region at a 15.6% CAGR, driven by China's sequencing capacity and India's GenomeIndia program . Europe follows with a 27.8% share, backed by Genomics England and the EU's Genome of Europe effort [5][6]. These regional dynamics position the Next Generation Sequencing Services Market for broad-based expansion through 2035.

## Key Report Takeaways

### • By Service Type

- Human Genome Sequencing Services held a 34.9% share of the Next Generation Sequencing Services Market in 2025, supported by rare-disease and population genomics demand.
- Single-Cell Sequencing Services are forecast to grow at a 15.8% CAGR through 2035 as cell-capture costs decline.

### • By Technology

- Sequencing-by-Synthesis (SBS) captured a 56.4% revenue share in 2025 on the strength of its installed base and accuracy.
- Nanopore Sequencing is the fastest-advancing platform, expanding at a 21.0% CAGR.

### • By Application

- [Clinical Diagnostics](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770) accounted for 42.5% of Next Generation Sequencing Services Market revenue in 2025, led by oncology profiling.
- Drug Discovery & Development is projected to post a 16.0% CAGR as sponsors embed genomic data in trials.

### • By End User

- Clinical Diagnostic Laboratories led with a 31.4% share in 2025, leveraging sample aggregation and payer contracts.
- Hospitals & Clinics are set to grow at a 16.3% CAGR as in-network genomic programs scale.

### • By Region

- North America held a 44.6% share in 2025.
- Europe captured a 27.8% share, anchored by national genomic medicine services.
- Asia-Pacific is forecast to grow at a 15.6% CAGR, the fastest of any region.

## Market Size and Forecast (2021–2035)

Historical values for the Next Generation Sequencing Services Market were built from provider revenue disclosures, laboratory test-volume data, and national program spending, then reconciled against primary interviews with laboratory directors, procurement leads, and sponsor-side genomics teams. Forecasts combine bottom-up sample-volume models with top-down validation against healthcare and R&D spending trends.

## Market Drivers

## Driver Impact Analysis

Impact percentages below indicate each driver's directional influence on the Next Generation Sequencing Services Market growth rate. They overlap and interact, so they should not be added together to reproduce the headline CAGR.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Declining per-genome sequencing costs | +2.8% | Global | Short-term (≤2 yr) | [1][2] |
| Reimbursement for comprehensive genomic profiling | +2.4% | North America, Europe | Medium-term (2–4 yr) | [3] |
| National population genomics programs | +2.2% | Europe, Middle East, Asia-Pacific | Long-term (≥4 yr) | [5][6] |
| Pharmaceutical outsourcing of sequencing | +1.9% | North America, Europe | Medium-term (2–4 yr) | [8] |
| AI-enabled interpretation pipelines | +1.5% | Global | Medium-term (2–4 yr) | [9] |
| Long-read and real-time platform maturation | +1.3% | Global | Long-term (≥4 yr) | [10][11] |
| Pathogen genomic surveillance infrastructure | +0.9% | Global, emerging markets | Short-term (≤2 yr) | [12] |

### Declining Per-Genome Sequencing Costs

Illumina's NovaSeq X pushed reagent cost per human genome close to USD 200, down from roughly USD 1,000 on the prior generation [1]. NHGRI tracking shows this decline outpacing semiconductor cost curves for over a decade [2]. Cheaper genomes widen the addressable buyer pool for the Next Generation Sequencing Services Market, because smaller hospitals and biotech firms can now order whole genomes instead of narrow panels. Service providers that run high-throughput instruments near full capacity capture most of this volume.

### Reimbursement for Comprehensive Genomic Profiling

CMS National Coverage Determination 90.2 covers FDA-approved NGS [companion diagnostics](https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077) for patients with advanced cancer [3]. The FDA's companion diagnostic list now includes dozens of NGS-based tests linked to targeted therapies . Each new biomarker-guided drug approval creates a corresponding testing requirement, and commercial payers typically follow Medicare's lead. Stable reimbursement lets reference laboratories commit to multi-year capacity investments with predictable returns.

### National Population Genomics Programs

Genomics England's Generation Study aims to sequence up to 100,000 newborns [5], while the EU's Genome of Europe project is building a reference cohort of more than 100,000 citizens [6]. India's GenomeIndia released 10,000 whole genomes in 2024 . These programs generate sustained, multi-year tenders, and many governments contract external providers rather than build public sequencing capacity from scratch.

### Pharmaceutical Outsourcing of Sequencing

IQVIA reports that emerging biopharma companies originate roughly two-thirds of the global drug pipeline [8]. These firms rarely own sequencing infrastructure and depend on service partners for target validation, patient stratification, and biomarker discovery. Multi-year master service agreements with sponsors deliver higher margins than academic per-sample work and smooth out cyclical research funding.

### AI-Enabled Interpretation Pipelines

Genomic data volumes were projected to reach 2–40 exabytes per year by 2025 [9], making manual variant review impractical. Providers now differentiate on [bioinformatics](https://www.marketresearchfuture.com/reports/bioinformatics-market-2265) data analysis, offering AI-based variant prioritization, automated reporting, and cloud delivery. Bundled interpretation raises average order value and shifts buyer selection toward vendors with validated analytical pipelines rather than raw sequencing capacity alone.

### Long-Read and Real-Time Platform Maturation

Pacific Biosciences' Revio system targets a HiFi human genome at about USD 1,000 [11], while Oxford Nanopore's latest chemistry delivers raw read accuracy above 99% [10]. Both platforms resolve structural variants and repeat expansions that short reads miss. Service labs offering long-read capacity capture constitutional disease and complex oncology referrals that previously went unresolved.

### Pathogen Genomic Surveillance Infrastructure

The WHO's 2022–2032 global genomic surveillance strategy calls on every member state to build or access sequencing capacity for pathogens with pandemic potential [12]. Many low- and middle-income countries meet this goal through outsourced or hub-based service models. Wastewater monitoring and hospital infection-control programs extend this demand beyond outbreak periods.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High data storage and computing costs | −1.4% | Global, emerging markets | Medium-term (2–4 yr) | [9] |
| Uneven reimbursement outside oncology | −1.2% | Global | Medium-term (2–4 yr) | [3] |
| Regulatory uncertainty for laboratory tests | −1.1% | North America, Europe | Short-term (≤2 yr) | [13][14] |
| Genomic data sovereignty restrictions | −1.0% | China, United States, Europe | Medium-term (2–4 yr) | [24] |
| Shortage of bioinformatics and genetic counseling talent | −0.9% | Global | Long-term (≥4 yr) | [16] |

### High Data Storage and Computing Costs

A single 30x human genome produces roughly 100 GB of raw data, and long-term retention requirements multiply that burden [9]. Cloud storage and compute fees can rival sequencing reagent costs for large cohorts. Smaller providers in price-sensitive markets struggle to absorb these expenses, which slows adoption of whole-genome services where budgets are tight.

### Uneven Reimbursement Outside Oncology

Coverage under NCD 90.2 focuses on advanced cancer [3]. Reimbursement for whole-genome testing in rare disease, pharmacogenomics, and hereditary screening varies widely by payer and country. Laboratories often face prior-authorization delays and denials, extending cash cycles and discouraging hospitals from ordering tests outside established oncology pathways.

### Regulatory Uncertainty for Laboratory Tests

The FDA finalized a rule in 2024 to regulate laboratory-developed tests as medical devices [13], before a federal court vacated it in March 2025. In Europe, Regulation (EU) 2024/1860 extended IVDR transition deadlines to 2027–2029 [14]. Shifting requirements complicate validation planning and delay launches of new clinical assays.

### Genomic Data Sovereignty Restrictions

China's Human Genetic Resources implementation rules, effective 2023, restrict export of genetic material and data [24]. U.S. legislative proposals targeting certain foreign genomics firms add further uncertainty for multinational sponsors. These barriers fragment global contracts and force duplicated capacity across jurisdictions.

### Shortage of Bioinformatics and Genetic Counseling Talent

Most markets have a demand for trained bioinformaticians and certified genetic counselors that exceeds supply. Large programs such as All of Us depend on limited analytical expertise to turn raw data into usable findings [16]. Talent gaps increase turnaround times and restrict how rapidly providers can develop clinical service lines.

## Opportunities

## Next-generation Sequencing Services Market Opportunities

### Single-Cell and Spatial Multiomics Outsourcing

Single-cell transcriptomics and spatial profiling require specialized instruments and workflows that most sponsors prefer not to own. Illumina's 2024 acquisition of Fluent BioSciences brought lower-cost, instrument-free single-cell capture into the mainstream [23]. Providers bundling single-cell, proteomic, and spatial readouts can win high-value target-discovery contracts.

### Emerging-Market Population Genomics

Saudi Arabia’s Saudi Genome Program , Emirati Genome Program with > 500, 000 genomes processed [22], and India’s GenomeIndia  are signals of demand extending outside traditional hubs. Such projects offer an entry point into places with inadequate domestic capacity for the Next Generation Sequencing Services Market, notably via public-private partnerships and in-country laboratory builds.

### Genomic Data Partnerships and New Business Models

The publication in 2023 of 500,000 complete genomes from UK Biobank revealed how pharmaceutical consortia will co-fund sequencing services in exchange for access to data [15]. Providers can transition from per-sample costs to data-partnership models that enable federated analysis, safe research environments, and royalty-linked partnerships that monetize de-identified datasets over many years.

### Newborn Genomic Screening

The Generation Study’s intention to sequence up to 100,000 infants may provide a blueprint for routine genetic screening [5]. If results justify a wider rollout, national health systems would need continuous, high-volume capacity with fast turnaround — something outsourced service providers with recognized clinical workflows are well suited for.

### Decentralized Infectious Disease Sequencing

Portable nanopore devices can facilitate epidemic response and hospital infection management, enabling sequencing in the field and near-patient [10]. Recurring revenue can be generated by providers through managed services that combine on-site devices with centralized analysis, for surveillance programs that are compatible with the WHO plan [12].

## Future Outlook

## Next-generation Sequencing Services Market Future Outlook

### AI-Native Genomic Interpretation

Interpretation, not sequencing, is becoming the bottleneck. With genomic data volumes measured in exabytes [9], AI models for variant classification, phenotype matching, and report drafting will move from pilot to standard practice by 2030. Providers that validate these tools clinically will capture a larger share of Next Generation Sequencing Services Market value, as buyers pay for answers rather than raw reads.

### Platform Price Competition and Service Economics

Roche's Sequencing by Expansion technology, unveiled in 2025 [20], joins Illumina, Element, Ultima, PacBio, and Oxford Nanopore in a crowded platform field. Intensifying competition should keep pushing per-sample costs down. Service providers gain from multi-platform flexibility, choosing the cheapest chemistry for each application and passing savings to price-sensitive customers.

### Multiomic Convergence

Thermo Fisher's USD 3.1 billion acquisition of Olink in 2024 [17] signals that proteomics and genomics are converging. Over the next decade, buyers will increasingly expect integrated genomic, transcriptomic, and proteomic readouts from a single provider. Single-cell and spatial methods will be central to these bundles.

### Data Governance and Sustainable Infrastructure

Regulators are tightening rules on genomic data residency and consent [24], while energy-intensive data centers attract scrutiny. Providers will invest in federated analysis, compressed data formats, and lower-carbon cloud regions. Strong governance will become a procurement requirement for national programs and pharmaceutical consortia.

## Segment Insights

## Next-generation Sequencing Services Market Segmentation

### By Service Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Human Genome Sequencing Services | 34.9% share | Rare-disease diagnostics and population cohorts |
| Single-Cell Sequencing Services | 15.8% CAGR | Oncology, immunology, and neuroscience research |
| Microbial Genome-Based Sequencing Services | USD 1.05 Billion | Infection control and metagenomic diagnostics |
| Gene Regulation Services | 16.5% share | Epigenetic and transcriptional studies |
| Other Service Type | USD 0.82 Billion | Targeted panels and specialty projects |

Within the Next Generation Sequencing Services Market, Human Genome Sequencing Services lead because national screening programs and rare-disease referrals generate steady, high-volume orders. Single-Cell Sequencing Services grow fastest as lower-cost capture methods make cell-level resolution routine in drug discovery. Microbial Genome-Based Sequencing Services gain ground in hospital infection control, where metagenomic tests outperform culture. Gene Regulation Services and Other Service Type offerings serve cost-sensitive projects that do not require complete genomes.

### By Technology

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Sequencing-by-Synthesis (SBS) | 56.4% share | High accuracy and large installed base |
| Ion Semiconductor Sequencing | USD 0.74 Billion | Rapid targeted oncology panels |
| Nanopore Sequencing | 21.0% CAGR | Long reads and real-time results |
| Single-Molecule Real-Time (SMRT) Sequencing | 18.2% CAGR | Structural variant resolution |

Sequencing-by-Synthesis (SBS) remains the workhorse of the Next Generation Sequencing Services Market, offering accuracy above 99% and flexible throughput for clinical and research work. Nanopore Sequencing grows fastest as improved chemistry enables single-assay detection of point mutations and structural variants. Single-Molecule Real-Time (SMRT) Sequencing fills gaps in complex constitutional disorders, while Ion Semiconductor Sequencing retains a niche in same-day targeted panels.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Clinical Diagnostics | 42.5% share | Oncology profiling and hereditary testing |
| Drug Discovery & Development | 16.0% CAGR | Target validation and trial stratification |
| Agriculture & Environmental | USD 0.48 Billion | Crop breeding and microbiome studies |
| Biotechnology & Genetic Research and Other Applications | 15.6% share | Academic and synthetic biology projects |

Clinical Diagnostics dominates the Next Generation Sequencing Services Market because biomarker-guided therapies require genomic testing before treatment. Drug Discovery & Development grows fastest as sponsors embed whole-exome and single-cell data into target selection and adaptive trials. Agriculture & Environmental work supports breeding and biodiversity programs, while Biotechnology & Genetic Research and Other Applications provide steady academic demand.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | 16.3% CAGR | In-network genomic medicine programs |
| Pharmaceutical & Biotech Companies | USD 1.48 Billion | Outsourced biomarker and discovery work |
| Clinical Diagnostic Laboratories | 31.4% share | Sample aggregation and payer contracting |
| Academic and Research Institutions | 19.8% share | Grant-funded cohort studies |
| Other End Users | USD 0.27 Billion | Forensic and agricultural customers |

Clinical Diagnostic Laboratories hold the largest position in the Next Generation Sequencing Services Market, drawing on high sample volumes, proprietary pipelines, and payer relationships. Hospitals & Clinics expand fastest as health systems launch internal genomic programs and partner with providers for overflow capacity. Pharmaceutical & Biotech Companies sign multi-year agreements, while Academic and Research Institutions depend on grant cycles.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 44.6% share | Oncology profiling, pharma outsourcing, population cohorts |
| Europe | 27.8% share | National genomic medicine services, IVDR compliance |
| Asia-Pacific | 15.6% CAGR | Domestic sequencing capacity, national genome projects |
| South America | USD 0.25 Billion | Oncology testing, academic research partnerships |
| Middle East and Africa | 14.1% CAGR | Government-funded population genomics |
| Total | USD 5.71 Billion | — |

Regional performance across the Next Generation Sequencing Services Market reflects differences in reimbursement depth, program funding, and laboratory density.

### North America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 86.2% share of region | Medicare coverage and dense reference laboratory networks |
| Canada | 13.9% CAGR | Provincial genomic medicine programs |
| Mexico | USD 0.08 Billion | Private oncology diagnostics growth |

The United States anchors the regional Next Generation Sequencing Services Market through NCD 90.2 coverage [3], a long list of FDA-recognized companion diagnostics , and large cohorts such as All of Us [16]. Labcorp's 2024 acquisition of select Invitae assets consolidated hereditary testing volumes [19]. Canada benefits from provincial programs integrating genome-wide testing into rare-disease care, while Mexico's growth is concentrated in private oncology networks.

### Europe

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | USD 0.36 Billion | Statutory insurance coverage for genome sequencing model project |
| UK | 24.6% share of region | NHS Genomic Medicine Service and Generation Study |
| France | 12.8% CAGR | France Genomic Medicine Plan 2025 |
| Italy | 9.4% share of region | Regional oncology testing networks |
| Spain | USD 0.11 Billion | Precision oncology programs in public hospitals |
| Nordic Countries | 13.6% CAGR | Biobank-linked research infrastructure |
| Russia | USD 0.05 Billion | Domestic research demand |
| Rest of Europe | 13.1% share of region | EU-funded genome initiatives |

Europe combines state-backed genomic medicine with stringent regulation. The UK leads through the NHS Genomic Medicine Service, Genomics England [5], and UK Biobank's 500,000-genome resource [15]. The Genome of Europe project coordinates cross-border reference data [6]. IVDR transition timelines [14] push laboratories toward accredited, well-documented service partners.

### Asia-Pacific

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 38.7% share of region | Domestic sequencing providers and hospital oncology demand |
| India | 18.4% CAGR | GenomeIndia and private diagnostics expansion |
| Japan | USD 0.21 Billion | Insurance-covered cancer genomic profiling |
| South Korea | 9.8% share of region | National bio big data project |
| ASEAN | 17.1% CAGR | Hub laboratories serving regional demand |
| Rest of Asia-Pacific | USD 0.09 Billion | Academic and agricultural genomics |

China dominates regional volume through large domestic providers, although human genetic resource rules [24] keep most data onshore. India's GenomeIndia release of 10,000 genomes  is catalyzing disease-specific follow-on studies. Japan reimburses comprehensive cancer genomic profiling, while ASEAN countries rely on hub laboratories in Singapore and Malaysia.

### South America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% share of region | Private oncology labs and research consortia |
| Argentina | 12.9% CAGR | Academic genomics collaborations |
| Rest of South America | USD 0.04 Billion | Infectious disease surveillance |

Brazil leads demand through private diagnostic chains and university research networks. Pathogen surveillance capacity built during the pandemic continues to support public health sequencing in line with WHO guidance [12]. Currency volatility and import duties on reagents remain the main barriers to faster regional growth.

### Middle East and Africa

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29.6% share of region | Saudi Genome Program |
| UAE | 16.2% CAGR | Emirati Genome Programme |
| South Africa | USD 0.04 Billion | Infectious disease and research genomics |
| Egypt | 13.2% CAGR | Egyptian Genome Project |
| Rest of MEA | 21.5% share of region | Donor-funded surveillance programs |

Gulf governments are the region's growth engine. Saudi Arabia's genome program  and the UAE's Emirati Genome Programme [22] fund large-scale sequencing for premarital screening and rare-disease care. South Africa's research base supports pathogen genomics, while Egypt is building national reference data.

## Competitive Benchmarking

## Competitive Benchmarking

The Next Generation Sequencing Services Market shows medium concentration, with an estimated HHI of 850–1,050 and the top five providers holding roughly 35–40% of revenue. Platform vendors with in-house service labs compete alongside global contract research providers and regional specialists. Differentiation increasingly rests on bioinformatics depth, clinical accreditation, and multiomic breadth rather than sequencing capacity alone.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Illumina | ~10–13% | Clinical services lab, whole-genome and exome services | Platform leader extending into single-cell and multiomics |
| BGI Genomics | ~7–9% | Whole-genome, reproductive health, infectious disease services | Cost leader with large Asia-Pacific footprint |
| Eurofins Scientific | ~6–8% | Genomic services, clinical and research sequencing | Broad laboratory network across Europe and North America |
| Thermo Fisher Scientific | ~5–7% | Ion Torrent services, Olink proteomics | Multiomic integration after Olink acquisition |
| Azenta Life Sciences | ~4–6% | GENEWIZ sequencing services, sample management | Research-focused provider with biorepository strength |
| Novogene | ~4–6% | Whole-genome, transcriptome, single-cell services | Price-competitive global research services |
| Labcorp | ~3–5% | Oncology and hereditary genomic testing | Clinical reach strengthened by Invitae assets |
| Quest Diagnostics | ~3–5% | Oncology profiling, hereditary testing | Large U.S. patient-service network |
| Macrogen | ~2–4% | Research sequencing, personal genomics | Strong presence in South Korea and Asia |
| Pacific Biosciences | ~1–3% | HiFi long-read sequencing access programs | Structural variant and complex genome specialist |
| Oxford Nanopore Technologies | ~1–3% | Real-time nanopore sequencing services | Portable and field sequencing leader |
| QIAGEN | ~1–3% | Sample preparation, bioinformatics software | Workflow and interpretation partner |

## Recent News & Developments

## Recent News & Developments

- UK Biobank (November 2023): Released whole-genome sequences for 500,000 participants, creating a benchmark resource that drives downstream analysis demand. [15]

- Illumina (June 2024): Completed the spin-off of GRAIL, refocusing on its core sequencing business. [18]
- European Commission (July 2024): Adopted Regulation (EU) 2024/1860, extending IVDR transition deadlines for in vitro diagnostics. [14]
- Thermo Fisher Scientific (July 2024): Completed its USD 3.1 billion acquisition of Olink, adding proteomics to its genomics portfolio. [17]
- Illumina (July 2024): Acquired Fluent BioSciences to offer lower-cost, scalable single-cell workflows. [23]
- Labcorp (August 2024): Acquired select Invitae assets, consolidating hereditary and oncology testing volumes. [19]
- Roche (February 2025): Unveiled Sequencing by Expansion technology, promising sharply shorter run times. [20]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The Next Generation Sequencing Services Market covers outsourced human, single-cell, microbial, and gene regulation sequencing services delivered on SBS, ion semiconductor, nanopore, and SMRT platforms to hospitals, laboratories, pharmaceutical companies, and research institutions. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 5.71 Billion |
| Market Size in 2035 | USD 20.25 Billion |
| CAGR (2026–2035) | 13.4% |
| Fastest Growing Segments | Nanopore Sequencing (21.0% CAGR); Single-Molecule Real-Time (SMRT) Sequencing (18.2% CAGR); Hospitals & Clinics (16.3% CAGR); Drug Discovery & Development (16.0% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Illumina, BGI Genomics, Eurofins Scientific, Thermo Fisher Scientific, Azenta Life Sciences, Novogene, Labcorp, Quest Diagnostics, Macrogen, Pacific Biosciences, Oxford Nanopore Technologies, QIAGEN |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should buyers evaluate vendors in the Next Generation Sequencing Services Market?**
A: Prioritize CLIA/CAP or ISO 15189 accreditation, documented turnaround times, and contract terms granting you raw-data ownership. Request concordance results against a Genome in a Bottle reference sample before committing volume.

**Q: Which contract models are common in the Next Generation Sequencing Services Market?**
A: Academic customers mostly pay per sample, while pharmaceutical sponsors sign multi-year master service agreements with volume tiers. Some providers now sell reserved run capacity, guaranteeing slots during peak trial enrollment.

**Q: Is short-read or long-read sequencing better for structural variant detection?**
A: Long-read platforms resolve large insertions, inversions, and repeat expansions that short reads frequently miss [11]. Many clinical labs pair short-read genomes with targeted long-read follow-up to balance cost and sensitivity.

**Q: How does data sovereignty affect outsourcing in the Next Generation Sequencing Services Market?**
A: China and the EU restrict cross-border transfer of genomic data [24]. Multinational trial sponsors often need in-country sequencing partners or federated analysis to stay compliant.

**Q: What role do contract research organizations play?**
A: CROs increasingly bundle sequencing into biomarker and companion diagnostic programs, acting as a single point of contact for sponsors. This channels a growing share of Next Generation Sequencing Services Market demand through partnerships rather than direct laboratory contracts.

**Q: Which emerging use cases could add demand after 2030?**
A: Multi-cancer early detection, transplant rejection monitoring, and wastewater pathogen surveillance are moving from pilots toward routine use. Each depends on high-volume, low-cost sequencing that suits outsourced service models.

**Q: What integration challenges do hospitals face with sequencing services?**
A: Hospitals struggle to feed structured variant reports into electronic health records and decision support tools. HL7 FHIR Genomics standards are narrowing this gap, which should lift hospital spending in the Next Generation Sequencing Services Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/next-generation-sequencing-services-market-67403*